Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sino Biopharm ADR (OP:SBHMY)

12.06 +0.79 (+7.05%)
Streaming Delayed Price Updated: 11:29 AM EDT, Jun 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sino Biopharm ADR

News headline image
Sino Biopharm (1177.HK) Announces 2025 Annual Results
From Sino Biopharmaceutical Limited
Via ACN Newswire
News headline image
Sino Biopharm (1177.HK) Announces 2025 Interim Results
From Sino Biopharmaceutical Limited
Via ACN Newswire
News headline image
Sino Biopharm (1177.HK) Announces 2024 Annual Results
From Sino Biopharmaceutical Limited
Via ACN Newswire
News headline image
Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results
From Sino Biopharmaceutical Limited
Via ACN Newswire
News headline image
Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership ↗
BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies... 
Via Talk Markets
News headline image
Week In Review: Betta Pharma Enters $392 Million Deal For C4 Therapeutics’ NSCLC Drug ↗
Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer drug from Boston’s C4 Therapeutics in a deal worth up to $392 million. Additionally, Lynk Pharma of Hangzhou... 
Via Talk Markets
News headline image
Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal ↗
Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up... 
Via Talk Markets
News headline image
Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug ↗
Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,... 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.